HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Comfrey Presents "Serious Health Hazard," ONPLDS Tells Industry

This article was originally published in The Tan Sheet

Executive Summary

Marketers of comfrey-containing dietary supplements should recall all such products or face direct enforcement action, FDA asserts in a July 6 letter sent to eight trade groups.

You may also be interested in...



Christopher Enterprises Comfrey Marketing For Internal Use Barred

Federal Trade Commission settlement provisions that restrict marketing of, and impose warning requirements on, Christopher Enterprises' comfrey-containing supplements will not apply if the products contain no pyrrolizidine alkaloids

Comfrey

FDA "would not necessarily object" to comfrey supplements that have had pyrrolizidine alkaloids removed during processing, agency notes in recent letter to AHPA. "We would expect such a product to be completely free of the pyrrolizidine alkaloids and not simply...processed to reduce the quantity of [PAs] present," FDA says. Letter clarifies July 6 notice to eight trade groups urging marketers to recall comfrey-containing supplements due to evidence linking PAs to liver damage (1"The Tan Sheet" July 9, p. 10). However, if a principal substance is removed from a dietary ingredient, a 75-day premarket notification is required, FDA notes. AHPA is seeking data from its members on PA-free analytical methods...

Comfrey

FTC action July 13 against comfrey marketer Western Botanicals (Fair Oaks, Calif.) is second one in two weeks. Decision is part of commission's "Operation Cure.All" crackdown on unsupported supplement claims. Stipulated permanent injunction bars defendant from future sale of internal comfrey products, external products without warnings; Western also is required to notify distributors, purchasers by mail. FDA issued a comfrey advisory July 6 following FTC action against comfrey supplement marketer Christopher Enterprises (1"The Tan Sheet" July 9, p. 10). Several trade groups have voiced support for comfrey actions and pointed to voluntary label programs already in place

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel